Phase 1 Study of Relative Bioavailability of PPI-668 New Tablet Versus Capsule Formulations

Study Overview
=================
Brief Summary
-----------------
This study will compare the blood levels of PPI-668 resulting from two different formulations - the current capsule and a new tablet, T003.

Official Title
-----------------
A Phase 1, Open-Label, Crossover Study to Evaluate the Relative Bioavailability of a New Tablet Formulation Versus the Current Capsule Formulation of PPI-668 in Healthy Adult Volunteers

Conditions
-----------------
Pharmacokinetic Assessments in Healthy Volunteers

Intervention / Treatment
-----------------
* Drug: PPI-668 tablet
* Drug: PPI-668 capsule


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have the ability to understand and sign a written informed consent form nonsmoker body mass index (BMI) of 18.0 to 29.9 kg/m2 (inclusive) HIV-1 antibody negative. hepatitis B (HBV) surface antigen negative. hepatitis C (HCV) antibody negative. Exclusion Criteria: Pregnant or lactating subjects. Have any serious or active medical or psychiatric illness which, in the opinion of the Investigator, would interfere with subject treatment, assessment, or compliance with the protocol. This would include renal, cardiac, hematologic, hepatic, pulmonary (including chronic asthma), endocrine (e.g., diabetes), central or peripheral nervous, gastrointestinal (including an ulcer), vascular, metabolic (thyroid disorders, adrenal disease), or immunodeficiency disorders, active infection, or malignancy that is clinically significant or requiring treatment. Have participated in an investigational trial involving administration of any investigational compound within 30 days prior to the study dosing. Current alcohol or substance abuse judged by the Investigator to potentially interfere with subject compliance. Have poor venous access and unable to donate blood. Have donated blood within 56 days of study dosing. Have donated plasma within 7 days of study dosing. Have taken any prescription medications or over-the-counter medications including herbal products within 28 days of commencing study drug dosing with the exception of vitamins and/or acetaminophen and/or ibuprofen and/or contraceptive medications.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PPI-668 tablet followed by capsule<br>On day 1, one 200 mg PPI-668 tablet will be administered. On day 6, two 100 mg PI-668 capsules will be administered. | Drug: PPI-668 tablet<br> <br> Drug: PPI-668 capsule<br> <br> |
| Experimental: PPI-668 capsule followed by tablet<br>On day 1, two 100 mg PI-668 capsules will be administered. On day 6, one 200 mg PPI-668 tablet will be administered. | Drug: PPI-668 tablet<br> <br> Drug: PPI-668 capsule<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PPI-668 area under the curve from time zero to infinity (AUC 0-inf) |  | days 1-8 | 
| PPI-668 maximum observed plasma concentration (Cmax) |  | Days 1-8 | 
| PPI-668 area under the curve from time zero to the last quantifiable concentration (AUC 0-t) |  | Days 1-8 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| assessments of adverse events |  | days 1-8 | 
| assessments of composite of clinical laboratory parameters |  | days 1-8 |